Sep 9
Getz, the Executive Director at the Tufts Center for the Study of Drug Development (CSDD), presented findings from a study they did with TransCelerate BioPharma, which sheds light on the volume and purpose of data collected in clinical trial protocols. His talk centered on a fundamental paradox in modern clinical research: While we have an incentive to manage and optimize data collection, our protocols often accumulate an excessive amount of information that isn’t directly relevant to demonstrating the safety and efficacy of a drug.
Read the full article by Clinical Leader here.
Related Blog Posts
Scrip Asks… What Does 2026 Hold For Biopharma? Part 4: R&D Innovation
Enthusiastic predictions from industry leaders for ongoing progress in obesity, oncology, immunology, neuroscience and more were supported by optimism for the potential of AI and other technological advances to enable breakthroughs in processes as well as pipelines. Read the full article featuring Rob DiCicco from Citeline here.
Digital Protocols Are At An Inflection Point: A Conversation With Novartis And TransCelerate Leaders
Interest in digital approaches to clinical protocols has grown steadily as sponsors, solution providers, sites, and regulators explore ways to make study planning and execution more efficient. Read the full article featuring Rob DiCicco from Clinical Leader here.
Scrip Asks… What Does 2026 Hold For Biopharma? Part 2: Competitive Dynamics – A Landscape Reshaped
Regulatory divergence across major markets is creating strategic complexity that compounds geographic competitive pressures. Read the full article featuring Allison Cuff Shimooka from Citeline here.